Quantcast

Latest Mdm2 Stories

2010-09-13 12:40:07

St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue St. Jude Children's Research Hospital investigators have identified a novel structure in cells that serves as a control switch in the body's system for eliminating damaged cells and also offers new therapeutic potential. The findings provide fresh...

2010-08-17 17:19:21

Findings show that rather than a straightforward "off-on" switch, the MDM2 oncogene is controlled by a more complicated "dimmer switch" that is sensitive to its changing environment Researchers at Beth Israel Deaconess Medical Center (BIDMC) have uncovered the genes that regulate MDM2, an oncogene that, in turn, regulates the tumor suppressor protein p53. But instead of an on-off switch for MDM2, the team found what looks like a dimmer switch, suggesting a more complicated signaling pathway...

2010-06-11 01:11:06

The research demonstrates that p53 is activated to control the creation of ova and spermatozoa Protein p53 is known as the guardian of the genome since it is basic for the genome's integrity by preventing the accumulation of mutations originating either by the cell's own mechanisms or by the action of external agents. The protein becomes activated in response to specific signals such as breaks in DNA. This activation implies a slowing of the cell's cycle which allows it to repair itself from...

2010-06-07 13:46:59

Protein p53 is also activated to control the creation of ova and spermatozoids Protein 53 is very important in protecting against cancer given that it prevents cancer-causing mutations from accumulating and its inactivation is closely linked to the proliferation of tumour cells. UAB lecturer Ignasi Roig participated in the study. Formed by an international research team, the study served to discover that this protein played an unexpected physiological role: it also becomes activated during...

2010-06-04 07:00:00

MALVERN, Pa., June 4 /PRNewswire/ -- Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY) covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor...

2010-03-29 09:40:00

St. Jude Children's Research Hospital investigators identify a new class of compounds targeting a protein implicated in promoting a variety of cancers, including a childhood eye tumor MEMPHIS, Tenn., March 29 /PRNewswire-USNewswire/ -- Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children's Research...

5f2982206645651affecb2b918acc39e1
2010-03-29 10:35:00

St. Jude Children's Research Hospital investigators identify a new class of compounds targeting a protein implicated in promoting a variety of cancers, including a childhood eye tumor Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children's Research Hospital scientists. The chemical is the first...

2010-02-17 11:00:00

PLEASANTON, Calif., Feb. 17 /PRNewswire/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes...

43d40e4b01dce2837780c7bec18ac480
2009-12-07 14:17:43

Discovery may lead to new treatments for late-stage cancers Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have determined how the protein Mdm2, which is elevated in late-stage cancers, disables genes that suppress the growth of tumors. The finding may lead to the development of new drugs for late stage breast cancer and other difficult to treat malignancies. The investigators have identified a...

2009-12-02 11:17:17

A large proportion of late-stage breast cancers that have spread to other parts of the body (metastatic breast cancers) are characterized by overexpression of the protein Mdm2. Lindsey Mayo and colleagues, at Indiana University School of Medicine, Indianapolis, have now determined what drives this increased Mdm2 expression and found that Mdm2 helps promote cancer cells take on more aggressive characteristics, making it a potential target for drugs to treat late-stage metastatic breast...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related